DTIL – Precision BioSciences Inc.
DTIL
$5.42Name : Precision BioSciences, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $134,018,696.00
EPSttm : -3.63
Precision BioSciences, Inc.
$5.42
DTIL — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
7.23
Margin Of Safety %
Put/Call OI Ratio
0.03
EPS Next Q Diff
-1.28
EPS Last/This Y
0.03
EPS This/Next Y
0.13
Price
6.03
Target Price
32
Analyst Recom
1
Performance Q
40.33
Upside
-1,218.6%
Beta
0.91
Ticker: DTIL
19 items
«
‹
of 1
›
»
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-02 | DTIL | 4.33 | 0.01 | 0.00 | 2098 |
| 2026-03-03 | DTIL | 4.34 | 0.01 | 0.00 | 2100 |
| 2026-03-04 | DTIL | 4.78 | 0.01 | 0.00 | 2104 |
| 2026-03-05 | DTIL | 4.52 | 0.01 | 0.00 | 2105 |
| 2026-03-06 | DTIL | 4.61 | 0.01 | 0.00 | 2103 |
| 2026-03-09 | DTIL | 4.71 | 0.01 | 0.24 | 2104 |
| 2026-03-10 | DTIL | 5.35 | 0.03 | 2.50 | 2289 |
| 2026-03-11 | DTIL | 5.06 | 0.03 | 0.11 | 2311 |
| 2026-03-12 | DTIL | 5.66 | 0.04 | 0.27 | 2317 |
| 2026-03-13 | DTIL | 5.67 | 0.04 | 0.27 | 2317 |
| 2026-03-17 | DTIL | 6.91 | 0.03 | 0.00 | 2337 |
| 2026-03-18 | DTIL | 7.01 | 0.03 | 0.08 | 2344 |
| 2026-03-19 | DTIL | 6.7 | 0.03 | 0.07 | 2344 |
| 2026-03-20 | DTIL | 6.5 | 0.03 | 0.00 | 2344 |
| 2026-03-23 | DTIL | 6.49 | 0.03 | 0.00 | 894 |
| 2026-03-24 | DTIL | 6.41 | 0.03 | 0.00 | 896 |
| 2026-03-25 | DTIL | 6.46 | 0.03 | 0.36 | 898 |
| 2026-03-26 | DTIL | 6.52 | 0.03 | 0.33 | 913 |
| 2026-03-27 | DTIL | 6.03 | 0.03 | 0.33 | 913 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
19 items
«
‹
Current Page1 of 1
›
»
19 items
«
‹
of 1
›
»
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-02 | DTIL | 4.33 | 69.9 | - | -6.16 |
| 2026-03-03 | DTIL | 4.36 | 69.9 | - | -6.16 |
| 2026-03-04 | DTIL | 4.78 | 69.9 | - | -6.16 |
| 2026-03-05 | DTIL | 4.53 | 69.9 | - | -6.16 |
| 2026-03-06 | DTIL | 4.61 | 69.9 | - | -6.16 |
| 2026-03-09 | DTIL | 4.71 | 69.9 | - | -6.16 |
| 2026-03-10 | DTIL | 5.34 | 69.9 | - | -6.16 |
| 2026-03-11 | DTIL | 5.07 | 69.9 | - | -6.16 |
| 2026-03-12 | DTIL | 5.64 | 69.9 | - | -6.16 |
| 2026-03-13 | DTIL | 5.67 | 69.9 | - | -6.16 |
| 2026-03-17 | DTIL | 6.93 | 69.9 | - | -6.16 |
| 2026-03-18 | DTIL | 7.05 | 69.9 | - | -6.16 |
| 2026-03-19 | DTIL | 6.70 | 69.9 | - | -6.16 |
| 2026-03-20 | DTIL | 6.51 | 63.8 | - | -3.53 |
| 2026-03-23 | DTIL | 6.51 | 63.8 | - | -3.53 |
| 2026-03-24 | DTIL | 6.41 | 63.8 | - | -3.53 |
| 2026-03-25 | DTIL | 6.47 | 63.8 | - | -3.53 |
| 2026-03-26 | DTIL | 6.52 | 63.8 | - | -3.53 |
| 2026-03-27 | DTIL | 6.03 | 63.8 | - | -3.53 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
19 items
«
‹
Current Page1 of 1
›
»
19 items
«
‹
of 1
›
»
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-02 | DTIL | -1.90 | 45.35 | 7.89 |
| 2026-03-03 | DTIL | -1.90 | 45.35 | 7.89 |
| 2026-03-04 | DTIL | -1.90 | 45.35 | 7.89 |
| 2026-03-05 | DTIL | -1.90 | 45.35 | 7.89 |
| 2026-03-06 | DTIL | -1.90 | 45.35 | 7.89 |
| 2026-03-09 | DTIL | -1.90 | 45.35 | 7.89 |
| 2026-03-10 | DTIL | -1.90 | 45.35 | 7.89 |
| 2026-03-11 | DTIL | -1.90 | 45.35 | 7.36 |
| 2026-03-12 | DTIL | -1.90 | 45.35 | 7.36 |
| 2026-03-13 | DTIL | -1.90 | 45.35 | 7.36 |
| 2026-03-17 | DTIL | -1.85 | 40.64 | 7.17 |
| 2026-03-18 | DTIL | -1.85 | 40.64 | 7.17 |
| 2026-03-19 | DTIL | -1.85 | 40.64 | 7.17 |
| 2026-03-20 | DTIL | -1.85 | 40.64 | 7.17 |
| 2026-03-23 | DTIL | -1.85 | 40.60 | 7.17 |
| 2026-03-24 | DTIL | -1.85 | 40.60 | 7.17 |
| 2026-03-25 | DTIL | -1.87 | 40.60 | 7.23 |
| 2026-03-26 | DTIL | -1.87 | 40.60 | 7.23 |
| 2026-03-27 | DTIL | -1.87 | 40.60 | 7.23 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
19 items
«
‹
Current Page1 of 1
›
»
Last Quarter Act. EPS
0.36
Avg. EPS Est. Current Quarter
-0.8
Avg. EPS Est. Next Quarter
-0.92
Insider Transactions
-1.87
Institutional Transactions
40.6
Beta
0.91
Average Sales Estimate Current Quarter
4
Average Sales Estimate Next Quarter
2
Fair Value
Quality Score
25
Growth Score
38
Sentiment Score
66
Actual DrawDown %
98.6
Max Drawdown 5-Year %
-99.2
Target Price
32
P/E
Forward P/E
PEG
P/S
4.34
P/B
1.57
P/Free Cash Flow
EPS
-5.18
Average EPS Est. Cur. Y
-3.53
EPS Next Y. (Est.)
-3.4
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-136.03
Relative Volume
1.95
Return on Equity vs Sector %
-76.9
Return on Equity vs Industry %
-60.7
EPS 1 7Days Diff
-0.4
EPS 1 30Days Diff
-0.42
EBIT Estimation
◆
DTIL
Healthcare
$6.02
📉
Swing / Pullback
Buy the dip on strong trends
WEAK
Trend
0/20
Pullback
2/25
Volume
3/15
Valuation
12/20
TP/AR
2/10
Options
6/10
RSI
57.8
Range 1M
57%
🚀
N/A
Momentum Growth
Ride accelerating trends
WEAK
Momentum
2/25
Growth
19/30
Estimates
0/20
Inst/Vol
12/15
Options
10/10
EPS Yr
17.4%
EPS NY
6.5%
52W%
47.6%
💎
N/A
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+431.6% upside
Quality
6/30
Valuation
16/30
Growth
13/25
Stability
7/10
LT Trend
1/5
Upside
+431.6%
Quality
25
Click a card to see score breakdown
Full Analysis →
Sector: Healthcare
Industry: Biotechnology
Employees: 68
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-DMD (Excision) for the treatment of Duchenne muscular dystrophy. In addition, the company develops PBGENE-3243 for the treatment of m.3243 associated mitochondrial diseases; and iECURE-OTC (Insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azercabtagene zapreleucel for autoimmune diseases and other indications; and iECURE, Inc., an ARCUS-mediated targeted gene insertion. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
DTIL
Latest News
—
Caricamento notizie per DTIL…
stock quote shares DTIL – Precision BioSciences Inc. Stock Price stock today
news today DTIL – Precision BioSciences Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch DTIL – Precision BioSciences Inc. yahoo finance google finance
stock history DTIL – Precision BioSciences Inc. invest stock market
stock prices DTIL premarket after hours
ticker DTIL fair value insiders trading